Albireo Pharma Inc Beta

Cos'è Beta di Albireo Pharma Inc?

Beta di Albireo Pharma Inc è 0.00

Qual è la definizione di Beta?



BETA indica se una azione è più o meno volatile rispetto al mercato nel suo complesso. Un beta inferiore a 1 indica che la azione è meno volatile rispetto al mercato, mentre un beta più di 1 indica che la azione è più volatile. La volatilità è misurata come la fluttuazione del prezzo attorno alla media.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta di aziende nel Health Care settore su NASDAQ rispetto a Albireo Pharma Inc

Cosa fa Albireo Pharma Inc?

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Aziende con beta simili a Albireo Pharma Inc